This edition of the Genetic Technology TOE depicts the current landscape and the new life sciences trends. Precision clinical trial studies, glucose monitoring through smartphones, and gene editing to modify epigenetics are illustrated in the TOE.
The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Recent Diagnostic and Biopharma Advances
- Advancing Precision Clinical Trial Studies
- Novel Smartphone Case for Monitoring Blood Glucose
- Modifying CRISPR Platform for Epigenetic Applications
- Gilead, Kite Set to Acquire Cell Design Labs
Clinical Trial Analysis and Industry Interactions
- Summary of Key Clinical Studies Conducted by Sanguine Biosciences and Salk Institute
- Summary of Key Contacts